Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
Lilly's Omvoh is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
Lilly's Jaypirca significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
